METASTATIC BLADDER UROTHELIAL CARCINOMA
Clinical trials for METASTATIC BLADDER UROTHELIAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC BLADDER UROTHELIAL CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC BLADDER UROTHELIAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New triple therapy aims to tame immunotherapy side effects in advanced cancers
Disease control OngoingThis study tests whether adding tocilizumab to two standard immunotherapy drugs (ipilimumab and nivolumab) can reduce severe side effects while still fighting cancer. About 35 adults with advanced melanoma, non-small cell lung cancer, or bladder cancer will receive the combinatio…
Matched conditions: METASTATIC BLADDER UROTHELIAL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 03:23 UTC
-
New hope for bladder cancer patients who Can't take standard chemo
Disease control OngoingThis study tests whether adding the chemotherapy drug eribulin to the immunotherapy atezolizumab works better than atezolizumab alone for people with advanced bladder cancer that has spread or come back. The trial includes 72 adults whose cancer cannot be treated with the standar…
Matched conditions: METASTATIC BLADDER UROTHELIAL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 03:17 UTC
-
Immunotherapy plus chemo shows promise against Tough-to-Treat cancers
Disease control OngoingThis early-phase trial studies whether adding the immunotherapy drug pembrolizumab to standard chemotherapy can help people with rare, aggressive small cell or neuroendocrine cancers of the bladder or prostate. About 15 participants with cancer that has spread will receive the co…
Matched conditions: METASTATIC BLADDER UROTHELIAL CARCINOMA
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New combo aims to stall advanced bladder cancer
Disease control OngoingThis study tests whether adding cabozantinib to avelumab (an immunotherapy) helps keep metastatic urothelial cancer from progressing after initial chemotherapy. About 654 adults with advanced bladder, kidney, or ureter cancer that has spread will receive either the combo or avelu…
Matched conditions: METASTATIC BLADDER UROTHELIAL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New combo aims to extend life in tough bladder cancer cases
Disease control OngoingThis study tests whether adding the drug eribulin to standard chemotherapy helps people with advanced bladder cancer live longer. It includes 184 adults whose cancer has spread and no longer responds to immunotherapy. The goal is to see if the new combination works better than us…
Matched conditions: METASTATIC BLADDER UROTHELIAL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
Could a common heart pill boost cancer immunotherapy?
Disease control OngoingThis study tests adding propranolol, a blood pressure drug, to standard immunotherapy for people with advanced bladder cancer that has spread. The goal is to see if the combination is safe and helps control the cancer. Only 6 adults took part, and the study is no longer recruitin…
Matched conditions: METASTATIC BLADDER UROTHELIAL CARCINOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated May 08, 2026 12:03 UTC
-
Bladder cancer breakthrough: stopping immunotherapy may be just as effective
Disease control OngoingThis study looks at whether people with advanced bladder cancer can stop taking immunotherapy drugs after about a year without hurting their chances of survival. The goal is to see if stopping early leads to fewer side effects, better quality of life, and lower costs, while still…
Matched conditions: METASTATIC BLADDER UROTHELIAL CARCINOMA
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 04, 2026 16:31 UTC
-
New drug combo shows promise for Tough-to-Treat bladder cancer
Disease control OngoingThis early-phase trial tests a combination of two drugs—erdafitinib and enfortumab vedotin—for people with advanced bladder cancer that has spread and has specific changes in the FGFR2/3 genes. The study includes about 24 adults whose cancer worsened after standard chemotherapy. …
Matched conditions: METASTATIC BLADDER UROTHELIAL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 26, 2026 19:38 UTC
-
Can a gene test tell who will respond to immunotherapy?
Knowledge-focused OngoingThis study looks at whether certain genetic changes in tumors can help predict if the immunotherapy drug nivolumab will work for people with advanced bladder cancer that has spread. Researchers are testing tumor samples for specific gene mutations and a protein called CXCL13. The…
Matched conditions: METASTATIC BLADDER UROTHELIAL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated May 17, 2026 03:18 UTC